Amneal shareholders elect all 11 directors, approve say-on-pay at annual meeting

Amneal Pharmaceuticals, Inc.

All 11 director nominees elected; votes ranged from 238.7M (Meister) to 254.4M (Yanai) for.
Advisory vote on NEO compensation approved with 254.4M for, 1.2M against.
Ratification of Ernst & Young as auditor for FY2024 passed with 279.1M for, 0.6M against.
Broker non-votes of ~24.1M shares on director election and say-on-pay proposals.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Amneal Pharmaceuticals, Inc. shareholders approved To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-02 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2024-05-02

Exact text from the filing

Proposal 3 : To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024: For Against Abstain Broker Non-Votes 279,106,284 624,760 38,456 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Amneal Pharmaceuticals, Inc. shareholders approved Election of director nominees to hold office until the 2025 Annual Meeting of Stockholders at the 2024-05-02 meeting.

Proposal: director election
Outcome: passed
Meeting: 2024-05-02

Exact text from the filing

Proposal 1 : To elect the following director nominees to hold office until the 2025 Annual Meeting of Stockholders and until their respective successors are elected and qualified: For Against Abstain Broker Non-Votes Emily Peterson Alva 253,927,467 1,736,375 40,449 24,065,209

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Amneal Pharmaceuticals, Inc. shareholders approved To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers at the 2024-05-02 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2024-05-02

Exact text from the filing

Proposal 2 : To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 254,365,134 1,199,935 139,222 24,065,209

View on SEC.gov

139 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-021107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.